TWI706937B - 製備蛋白質去乙醯酶抑制劑之方法 - Google Patents

製備蛋白質去乙醯酶抑制劑之方法 Download PDF

Info

Publication number
TWI706937B
TWI706937B TW105118213A TW105118213A TWI706937B TW I706937 B TWI706937 B TW I706937B TW 105118213 A TW105118213 A TW 105118213A TW 105118213 A TW105118213 A TW 105118213A TW I706937 B TWI706937 B TW I706937B
Authority
TW
Taiwan
Prior art keywords
compound
acid
reacting
preparing
specific embodiment
Prior art date
Application number
TW105118213A
Other languages
English (en)
Chinese (zh)
Other versions
TW201718517A (zh
Inventor
法薩尼 賽迪
杜瑟 約翰Ｈ 凡
Original Assignee
美商艾斯特隆製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾斯特隆製藥公司 filed Critical 美商艾斯特隆製藥公司
Publication of TW201718517A publication Critical patent/TW201718517A/zh
Application granted granted Critical
Publication of TWI706937B publication Critical patent/TWI706937B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW105118213A 2015-06-08 2016-06-08 製備蛋白質去乙醯酶抑制劑之方法 TWI706937B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172624P 2015-06-08 2015-06-08
US62/172,624 2015-06-08

Publications (2)

Publication Number Publication Date
TW201718517A TW201718517A (zh) 2017-06-01
TWI706937B true TWI706937B (zh) 2020-10-11

Family

ID=56264043

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105118213A TWI706937B (zh) 2015-06-08 2016-06-08 製備蛋白質去乙醯酶抑制劑之方法

Country Status (11)

Country Link
US (1) US10144714B2 (enExample)
EP (1) EP3303304B1 (enExample)
JP (1) JP6873053B2 (enExample)
CN (1) CN107922352B (enExample)
AR (1) AR105812A1 (enExample)
AU (2) AU2016276573A1 (enExample)
CA (1) CA2988594C (enExample)
ES (1) ES2769255T3 (enExample)
MX (1) MX369349B (enExample)
TW (1) TWI706937B (enExample)
WO (1) WO2016200930A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601655A (en) * 2010-01-22 2014-10-31 Acetylon Pharmaceuticals Inc Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
CN107922352B (zh) 2015-06-08 2021-08-06 埃斯泰隆制药公司 制备蛋白质脱乙酰酶抑制剂的方法
TW201718516A (zh) 2015-06-08 2017-06-01 艾斯特隆製藥公司 組蛋白去乙醯酶抑制劑之晶形
US11298354B2 (en) * 2016-06-09 2022-04-12 Dana-Farber Cancer Institute, Inc. Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors
ES2929032T3 (es) 2016-08-08 2022-11-24 Acetylon Pharmaceuticals Inc Combinaciones farmacéuticas de inhibidores de histona desacetilasa 6 y anticuerpos inhibidores de CD20 y usos de los mismos
WO2018098168A1 (en) 2016-11-23 2018-05-31 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054099A1 (en) * 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
JPWO2002074298A1 (ja) 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
CN1582277A (zh) 2001-11-01 2005-02-16 詹森药业有限公司 用作糖原合酶激酶3β抑制剂的酰胺衍生物
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
EP1644323B1 (en) 2003-07-07 2015-03-18 Georgetown University Histone deacetylase inhibitors and methods of use thereof
EP1745022B1 (en) 2004-04-05 2014-08-13 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
EP1940805A4 (en) 2005-08-26 2009-11-11 Methylgene Inc BENZODIAZEPIN AND BENZOPIPERAZINANALOGA AS INHIBITORS OF HISTONDEACETYLASE
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
AU2007248656B2 (en) 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
WO2007144341A1 (en) 2006-06-12 2007-12-21 Vrije Universiteit Brussel Differentiation of rat liver epithelial cells into hepatocyte-like cells
ES2288802B1 (es) 2006-07-07 2008-12-16 Universidad De Granada Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas.
CA2662580C (en) 2006-09-11 2013-05-21 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
WO2009104696A1 (ja) 2008-02-19 2009-08-27 株式会社アーネストメディスン 身体機能の回復に有用な経口又は経腸組成物
US8440716B2 (en) 2008-07-23 2013-05-14 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
US8716326B2 (en) 2009-05-15 2014-05-06 Korea Research Institute Of Chemical Technology Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
WO2011075517A1 (en) * 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
US20130040998A1 (en) 2010-01-08 2013-02-14 Dana-Farber Cancer Institute, Inc. Fluorinated hdac inhibitors and uses thereof
NZ601655A (en) * 2010-01-22 2014-10-31 Acetylon Pharmaceuticals Inc Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
EP2571352A4 (en) 2010-05-21 2014-09-17 Sloan Kettering Inst Cancer SELECTIVE HDAC HEMMER
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
PL2640709T3 (pl) 2010-11-16 2016-10-31 Związki pirymidynohydroksyamidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania”
JP6169076B2 (ja) 2011-07-20 2017-07-26 ザ ジェネラル ホスピタル コーポレイション 骨疾患の処置のためのヒストン脱アセチル化酵素６選択的阻害剤
WO2013048949A2 (en) * 2011-09-26 2013-04-04 Bristol-Myers Squibb Company Selective nr2b antagonists
JP5724851B2 (ja) * 2011-11-30 2015-05-27 東レ株式会社 Ｎ−（ヨードフェニル）ピリミジニルアミン誘導体の製造方法
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US20150250786A1 (en) 2012-10-12 2015-09-10 The Trustees Of The University Of Pennsylvania Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
WO2014121062A1 (en) 2013-02-01 2014-08-07 Acetylon Pharmaceuticals, Inc. Selective hdac3 inhibitors
EP3004141A4 (en) 2013-06-03 2017-05-31 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma
WO2015042418A1 (en) 2013-09-20 2015-03-26 Acetylon Pharmaceuticals, Inc. Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor
JP2016536354A (ja) 2013-10-10 2016-11-24 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との組み合わせ
ES2862126T3 (es) 2013-10-10 2021-10-07 Acetylon Pharmaceuticals Inc Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa
US20150105383A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma
KR20160060143A (ko) 2013-10-11 2016-05-27 에이스틸론 파마수티컬스 인코포레이티드 히스톤 디아세틸라아제 억제제와 면역조절성 약물의 조합물
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
ES2806258T3 (es) 2013-12-03 2021-02-17 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
WO2015095632A1 (en) 2013-12-20 2015-06-25 Acetylon Pharmaceuticals, Inc. Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
US20150359794A1 (en) 2014-06-13 2015-12-17 Buck Institute For Research On Aging Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation
SG11201700094TA (en) 2014-07-07 2017-02-27 Acetylon Pharmaceuticals Inc Treatment of leukemia with histone deacetylase inhibitors
US20160137630A1 (en) 2014-10-08 2016-05-19 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
WO2016090230A1 (en) 2014-12-05 2016-06-09 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds for treating peripheral neuropathy
BR112017012504A2 (pt) 2014-12-12 2018-01-09 Acetylon Pharmaceuticals, Inc. derivados de piperidina como inibidores de hdac1/2
WO2016168647A1 (en) 2015-04-17 2016-10-20 Acetylon Pharmaceuticals Inc. Treatment of neuroblastoma with histone deacetylase inhibotrs
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
CN107922352B (zh) 2015-06-08 2021-08-06 埃斯泰隆制药公司 制备蛋白质脱乙酰酶抑制剂的方法
TW201718516A (zh) 2015-06-08 2017-06-01 艾斯特隆製藥公司 組蛋白去乙醯酶抑制劑之晶形
ES2929032T3 (es) 2016-08-08 2022-11-24 Acetylon Pharmaceuticals Inc Combinaciones farmacéuticas de inhibidores de histona desacetilasa 6 y anticuerpos inhibidores de CD20 y usos de los mismos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054099A1 (en) * 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors

Also Published As

Publication number Publication date
AR105812A1 (es) 2017-11-15
WO2016200930A9 (en) 2017-02-23
CA2988594C (en) 2023-08-15
AU2016276573A1 (en) 2018-01-04
EP3303304B1 (en) 2019-11-20
EP3303304A1 (en) 2018-04-11
US10144714B2 (en) 2018-12-04
AU2020267299B2 (en) 2022-07-07
US20160355486A1 (en) 2016-12-08
CN107922352B (zh) 2021-08-06
WO2016200930A1 (en) 2016-12-15
ES2769255T3 (es) 2020-06-25
CN107922352A (zh) 2018-04-17
TW201718517A (zh) 2017-06-01
CA2988594A1 (en) 2016-12-15
JP6873053B2 (ja) 2021-05-19
AU2020267299A1 (en) 2020-12-10
JP2018518486A (ja) 2018-07-12
MX369349B (es) 2019-11-06
MX2017015900A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
CN107922352B (zh) 制备蛋白质脱乙酰酶抑制剂的方法
AU2014339136B2 (en) Process for the preparation of a PDE4 inhibitor
WO2017221189A1 (en) An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
KR102266680B1 (ko) 벨리노스테트의 다형태 및 이의 제조 방법
WO2014020555A2 (en) An improved process for the preparation of dabigatran etexilate mesylate
CN110691771A (zh) 顺式-对位取代的环己基氨基腈盐及其制备方法
WO2013065063A1 (en) Anhydrous form of dasatinib, process for its preparation and its use
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
CN117897387A (zh) Glp-1受体激动剂中间体的制备方法
US20070203176A1 (en) Crystalline forms of dolasetron base and processes for preparation thereof
JP2026512004A (ja) ４－アミノ－５－メチル－（１ｈ）－ピリジン－２－オンの製造のための方法
WO2014096373A1 (en) Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
US20240010632A1 (en) Solid state forms of erdafitinib salts and processes for preparation of erdafitinib
US20150315164A1 (en) Process for preparing amorphous cabazitaxel
JP7492997B2 (ja) オラパリブの製造方法
WO2015104602A2 (en) A process for the preparation of anagliptin and its intermediates thereof
JP5234856B2 (ja) Ｎｐｙｙ５受容体拮抗作用を有する化合物の結晶
CN105121417B (zh) 经取代噻唑基乙酸三乙胺盐的结晶型
JP3884063B2 (ja) セフカペンピボキシルのメタンスルホン酸塩
HK40096314A (zh) 用於合成5-{5-氯-2-[(3s)-3-[(吗啉-4-基)甲基]-3，4-二氢异喹啉-2(1h)-羰基]苯基}-1，2-二甲基-1h-吡咯-3-甲酸衍生物的新方法及其在生产药物化合物中的应用
JP2025517548A (ja) ４－置換２－オキサゾリジノンの調製プロセス
WO2022034427A1 (en) An improved process for the preparation of 4-oxoisotretinoin
JP2010526126A (ja) バルサルタンの製造方法